Geode Capital Management
DYN icon

Geode Capital Management’s Dyne Therapeutics DYN Stock Holding History

Geode Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.2M Buy
3,743,427
+239,313
+7% +$4.45M ﹤0.01% 1322
2026
Q1 		$63.5M Buy
3,504,114
+240,685
+7% +$4.15M ﹤0.01% 1360
2025
Q4 		$63.8M Buy
3,263,429
+395,824
+14% +$7.5M ﹤0.01% 1342
2025
Q3 		$36.3M Buy
2,867,605
+613,935
+27% +$7M ﹤0.01% 1684
2025
Q2 		$21.5M Buy
2,253,670
+298,165
+15% +$3.28M ﹤0.01% 1917
2025
Q1 		$20.5M Buy
1,955,505
+68,176
+4% +$975K ﹤0.01% 1888
2024
Q4 		$44.5M Buy
1,887,329
+27,916
+2% +$826K ﹤0.01% 1500
2024
Q3 		$66.8M Buy
1,859,413
+84,760
+5% +$3.37M 0.01% 1251
2024
Q2 		$62.6M Buy
1,774,653
+467,049
+36% +$13.6M 0.01% 1199
2024
Q1 		$37.1M Buy
1,307,604
+374,766
+40% +$8.48M ﹤0.01% 1557
2023
Q4 		$12.4M Buy
932,838
+75,128
+9% +$734K ﹤0.01% 2213
2023
Q3 		$7.69M Buy
857,710
+118,524
+16% +$1.28M ﹤0.01% 2415
2023
Q2 		$8.32M Buy
739,186
+170,664
+30% +$2.01M ﹤0.01% 2395
2023
Q1 		$6.55M Buy
568,522
+21,967
+4% +$285K ﹤0.01% 2506
2022
Q4 		$6.33M Buy
546,555
+12,938
+2% +$150K ﹤0.01% 2527
2022
Q3 		$6.78M Buy
533,617
+34,499
+7% +$396K ﹤0.01% 2502
2022
Q2 		$3.43M Buy
499,118
+10,316
+2% +$71.1K ﹤0.01% 2905
2022
Q1 		$4.71M Buy
488,802
+5,856
+1% +$49.9K ﹤0.01% 2827
2021
Q4 		$5.74M Buy
482,946
+67,422
+16% +$948K ﹤0.01% 2821
2021
Q3 		$6.75M Buy
415,524
+877
+0.2% +$15.5K ﹤0.01% 2733
2021
Q2 		$8.72M Buy
414,647
+123,751
+43% +$2.33M ﹤0.01% 2556
2021
Q1 		$4.52M Buy
290,896
+54,891
+23% +$1.06M ﹤0.01% 2841
2020
Q4 		$4.96M Buy
+236,005
New +$4.67M ﹤0.01% 2609

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management's DYN Position: Q2 2026 in Review

Geode Capital Management increased its Dyne Therapeutics (DYN) stake by 6.8% in Q2 2026, buying an estimated $4.45M and bringing the position to 3,743,427 shares worth $83.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1322.

Geode Capital Management first reported a position in DYN in Q4 2020 and has held it in 23 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Geode Capital Management held 3,743,427 shares of Dyne Therapeutics worth $83.2M as of Q2 2026.
  • Geode Capital Management bought 239,313 Dyne Therapeutics shares in Q2 2026, an estimated $4.45M.
  • Dyne Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1322 holding.
  • Geode Capital Management first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.